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Oncogenic p21ras proteins can only exert their stimulation of cellular proliferation when plasma membraneassociated. This membrane association has an absolute
requirement for post-translational modification with
isoprenoids. The mechanism by which isoprenoids participate in the specific association of p21ras with plasma
membranes is the subject of this report. We present in
vitro evidence for a plasma membrane binding protein
for p21ras that can recognize the isoprenoid substituent
and, therefore, may facilitate the localization of p21ras.

Post-translational modification with isoprenoids results in
considerable structural diversity at the carboxyl terminus of
many proteins. Four such carboxyl-terminal structural motifs
have been identified (for review see Ref. 1). These are farnesylated-methylated cysteine, geranylgeranylated-methylated
cysteine, digeranylgeranylated vicinal cysteines of the -CC rab
proteins, and digeranylgeranylated residue-interrupted cysteines of the -CXC rab proteins. The carboxyl-terminal cysteine
of the -CXC rabs is methylated, whereas the carboxyl-terminal
cysteine of the -CC rabs is not. Since these modifications always increase the hydrophobic character of the substituted
proteins, it is generally assumed that they are involved in the
association of proteins so modified with lipid bilayer membranes. This assumption is supported by the observation that
most prenylated proteins are bound to cellular membranes, at
least under some physiological conditions.
A more recent hypothesis for the function of protein prenylation that is more in keeping with the observed structural
diversity and membrane specificity is that these lipid modifications also serve to mediate protein-protein interactions (2). A
well studied example of this function for protein prenylation is
the heterodimeric association of rab proteins with GDP dissociation inhibitor molecules to form soluble complexes that appear to be dependent on the digeranylgeranylation of the rab
proteins (3). Another recent example from our laboratory is the
mechanism of endoproteolytic cleavage of the farnesylated prelamin A molecule, which is mediated by an enzyme that possesses a specific farnesyl binding site (4).
It has been noted that it is possible that even membraneassociated prenylated proteins may utilize a polyisoprenoid-dependent protein-protein interaction for membrane binding (2).
Recognition of the polyisoprenoid and other structural elements of the protein by membrane receptors could confer the
necessary localization of particular prenylated proteins to par* This research was supported by American Cancer Society Grant
BE-21. The costs of publication of this article were defrayed in part by
the payment of page charges. This article must therefore be hereby
marked “advertisement” in accordance with 18 U.S.C. Section 1734
solely to indicate this fact.
‡ To whom correspondence should be addressed. Tel.: 423-439-8367;
Fax: 423-439-8235; E-mail: sinensky@etsu-tn.edu.

ticular subcellular compartments. Sequestration of the polyisoprenoid would be important in preventing nonspecific association of the protein with inappropriate membranes.
Farnesylated proteins are found in a number of cellular
compartments (1) including plasma membrane (p21ras, g-transducin), peroxisomes (PxF) and nuclei (lamin B, prelamin A).
For the naturally occurring forms of N, H, and K p21ras, it is
clear that plasma membrane localization shows an absolute
requirement for farnesylation (5), yet the occurrence of farnesylated proteins in other compartments suggests the existence
of some high affinity plasma membrane receptor that can recognize not only the isoprenoid but other structural features of
the protein as well. Studies on site-directed mutagenic alterations of p21ras proteins are consistent with this concept and
have clearly identified the hypervariable region of p21ras as a
second domain that specifies its plasma membrane localization
(6). In this report we present quantitative in vitro binding
studies that confirm the existence of a high affinity plasma
membrane receptor for p21ras.
MATERIALS AND METHODS

NIH3T3 Mouse Fibroblast Culture and Plasma Membrane Isolation—NIH3T3 mouse fibroblast cultures were grown in Dulbecco’s modified Eagle’s medium (high glucose) (Nova-Tech, Inc.) supplemented
with 10% fetal bovine serum (v/v) (Life Technologies, Inc.), 100 units/ml
penicillin, 100 mg/ml streptomycin, and 1 mg/ml amphotericin B. Twenty-four h before harvesting the cells for plasma membrane isolation,
culture media was supplemented with 8 mg/ml lovastatin to deplete the
association of endogenous p21ras with the plasma membrane.
A highly enriched plasma membrane fraction from NIH3T3 cells was
isolated as described (7). A protease inhibitor mix (1 mM each of antipain, aprotinin, bestatin, chymostatin, pepstatin A, leupeptin, and
phenylmethylsulfonyl fluoride) was added to the plasma membrane
fractions that were stored at 270 °C until used. The purity of plasma
membrane fraction was assessed via marker enzyme activities of 59nucleotidase (8) and glucose 6-phosphatase (9).
Generation of Recombinant Baculovirus-expressing His-tagged H, N,
and K p21ras, CVLL-p21Ha-ras and Lamin B; Purification of Recombinant Proteins and Iodination of p21Ha-ras—Recombinant baculovirusexpressing p21Ha-ras with a histidine tag affixed to its N terminus was
a gift from Dr. Sandra L. Hoffmann (University of Texas Southwestern
Medical Center, Dallas, TX). A BamHI/SalI fragment containing fulllength coding sequence of p21Ki-ras4B and a BamHI/HindIII fragment
containing full-length sequence of p21N-raswere cloned into compatible
cloning sites of pBlueBacHis2 vector (Invitrogen, San Diego, CA). The
constructs were cotransfected with Bac-N-Blue baculovirus DNA into
sf-9 cells (Invitrogen) with the aid of a cationic liposome-mediated
transfection kit (Invitrogen) employed according to the manufacturer’s
instructions. The recombinant baculoviruses were screened for and
isolated in sf-9 cells as described (10). A single virus clone for each of the
proteins was chosen for all further experimentation. Approximately,
5 3 106 sf-9 cells (Invitrogen)/75-cm2 flask were infected (;1 plaqueforming unit/cell) with recombinant baculoviruses derived from
p21Ha-ras, p21Ki-ras, and p21N-ras constructs, respectively. The infected
cells were grown in complete TNM-FH media (Invitrogen) supplemented with 10 mg/ml gentamicin at 27 °C for 48 h. The infected sf-9
cells were collected by centrifugation and after several washings with
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PBS, were processed for membrane and cytoplasmic fractions isolation
(11, 12). Both cytoplasmic- and membrane-associated forms of recombinant p21Ha-ras and membrane-associated forms of p21Ki-ras and
p21N-ras were purified via metal affinity chromatography Xpress System (Invitrogen) and imidazole elution (50 –75 mM). Recombinant baculovirus-expressing CVLL-p21Ha-ras was a gift from (Dr. Paul
Kirschmeier, Schering-Plow Research Institute, Kenilworth, NJ). sf-9
cells were infected with recombinant baculovirus-expressing CVLLp21Ha-ras as above, and the resultant protein was purified as described
(10). A highly purified preparation of lamin B was obtained from rat
liver using published procedures (13).
Recombinant p21Ha-ras derived from the membrane fraction of infected sf-9 cells was tagged with 125I (NEN Life Science Products/
Dupont) in the presence of Iodo-Beads (Pierce) according to the manufacturer’s instructions. Unbound 125I was removed via dialysis.
Binding of 125I-labeled p21Ha-ras to NIH3T3 Plasma Membranes and
Competition Assays—Aliquots of plasma membranes (100 mg of protein)
were incubated with varying concentrations of 125I-p21Ha-ras (5–150 nM)
with or without a 100-fold excess of unlabeled p21Ha-ras in a total
volume of 100 ml. The incubation medium consisted of phosphatebuffered saline containing 5 mM MgCl2, 30 mM guanosine 59-diphosphate, 0.1% bovine serum albumin, 0.5 M NaCl, and 0.8% Triton X-100.
The binding of the radioactive ligand was allowed to proceed for 1 h at
25 °C. Incubations were terminated by the addition of ice-cold PBS
containing 0.8% Triton X-100 and 0.1% bovine serum albumin. The
unbound radioactivity was removed via filtration of the reaction mixture through Whatman glass microfiber filters. The filters were washed
.6 times with PBS containing 0.8% Triton X-100 and 0.1% bovine
serum albumin and air-dried, and radioactivity was counted in a
gamma counter.
A time course experiment for binding was performed for 15, 30, 45,
60, and 75 min, utilizing the optimal conditions outlined above. Saturation of the binding was observed after 45 min, and therefore all
experiments were conducted for 1 h. To determine reversibility of binding, matched samples of plasma membranes (100 mg of protein) were
incubated with 125I-p21Ha-ras (125 nM), and the binding of the radioactive ligand was allowed to proceed at 25 °C. After a 1-h incubation, a
100-fold excess of unlabeled p21Ha-ras was added to one set of samples,
and incubation was continued for an additional 1 h. Incubations were
then terminated by the addition of ice-cold PBS containing 0.8% Triton
X-100 and 0.1% bovine serum albumin. The reaction mixture was then
centrifuged at 13,000 3 g for 15 min, and the difference between the
membrane-bound counts in the presence and absence of excess unlabeled p21Ha-ras was determined.
To study the effect of different competitors (non-farnesylated
p21Ha-ras, bovine serum albumin, p21N-ras p21Ki-ras, CVLL-p21Ha-ras,
rat liver lamin B, LLGNSSPRTQSPQNCfarnesyl, and N-acetyl farnesyl
methyl cysteine) on binding of iodinated p21Ha-ras to plasma membranes, varying concentrations (5 nM to 5 mM) of competitors were
added with 125I-p21Ha-ras (50 nM) under binding conditions outlined
above.
Nonlinear regression analysis of saturation binding and competitive
inhibition data were performed with SigmaPlot (Jandel Scientific, San
Rafael, CA). Scatchard plot analysis and calculations of IC50 values
were performed as described (14) with the linear regression performed
with Sigma Plot.
To evaluate whether the binding of p21Ha-ras to plasma membrane is
dependent on p21Ha-ras being bound to GTP or GDP, the binding studies
were carried out in the presence of 30 mM GDP or 25 mM GTPgS (Biomol)
under the conditions outlined for binding of 125I-labeled p21Ha-ras to
NIH3T3 plasma membranes above. These concentrations of unbound
ligand are approximately 1,000-fold excess to the concentration of GDPloaded p21Ha-ras, which gives half-maximal binding to plasma membranes. Binding reaction mixes were preincubated at 37 °C for 100 min
in the absence of membranes to allow nucleotide exchange to occur (15)
and transferred to a 25 °C water bath, and the binding reaction was
initiated by the addition of membranes.
Ligand Blotting Assays—Ligand blots were performed by a previously described method (16) with some modifications. Approximately 25
mg of NIH3T3 plasma membrane proteins were separated via SDSpolyacrylamide gel electrophoresis and transferred onto nitrocellulose
membranes. The blots were incubated in PBS containing 0.3% Tween,
0.5% Triton X-100, 5 mM MgCl2, 30 mM guanosine 59-diphosphate, 0.1%
bovine serum albumin, and 125I-p21Ha-ras (50 nM) with or without a
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The abbreviations used are: PBS, phosphate-buffered saline;
GTPgS, guanosine 59-O-(3-thiotriphosphate).

FIG. 1. SDS-polyacrylamide gel electrophoresis analysis of the
baculovirus-generated p21ras proteins. A Coomassie-stained 10%
polyacrylamide minigel with membrane-associated p21Ha-ras (lane 1),
cytosolic p21Ha-ras (lane 2), CVLL-p21Ha-ras (lane 3), p21Ki-ras (lane 4),
p21N-ras (lane 5), and lamin B from rat liver (lane 6) is shown.

100-fold excess of unlabeled p21Ha-ras with constant shaking at 25 °C.
After an 18-h incubation, blots were washed (.5 times) with PBS
containing 0.3% Tween and 0.5% Triton X-100, air-dried, and exposed
to Kodak X-Omat AR film at 270 °C.
Binding of Iodinated p21Ha-ras with Trypsin-treated Plasma Membranes—To determine if the binding of iodinated p21Ha-ras is to the
protein component(s) of the plasma membrane, NIH3T3 plasma
membranes were pretreated with trypsin (10 mg/ml) for 30 min at
25 °C followed by the addition of protease inhibitor mix. For control
experiments, trypsin was inactivated with protease inhibitor mix and
then added to the binding reaction mixture. For other series of experiments, plasma membrane proteins were also inactivated by incubation at 100 °C for 5 min. The binding studies were carried out
exactly as above.
Other Assays—Protein concentrations were determined by BCA
method (Pierce). N-Acetyl farnesyl methyl cysteine was prepared by
acid-catalyzed methylation of commercial N-acetyl farnesyl cysteine
(Calbiochem) as described previously (17). Gas-liquid chromatographic
analysis of the radiolabeled isoprenoid group of baculovirus-generated
p21Ha-ras was done after Raney nickel cleavage of immunoprecipitated
[3H]mevalonate-labeled protein, as described previously (18).
RESULTS

Saturation Binding of Farnesylated p21Ha-ras to 3T3 Cell
Plasma Membranes—Farnesylated, geranylgeranylated, and
nonprenylated p21Ha-ras proteins were synthesized in the baculovirus insect cell expression system, and the proteins were
purified to homogeneity as described under “Materials and
Methods” (Fig. 1). All of the baculovirus-generated p21Ha-ras
proteins showed immunoreactivity with Y13–259 antibody in
Western blots (data not shown). Synthesis of protein in the
presence of [3H]mevalonate followed by immunoprecipitation
gave rise to labeled material from membranes. This material
was analyzed for farnesylation by Raney nickel cleavage followed by radiolabeled gas-liquid chromatography and radiodetection (Fig. 2) as described previously (18). These results further demonstrate that we have prepared bona-fide p21Ha-ras in
sf-9 insect cells, as has also been reported elsewhere (11, 19 –21).
NIH3T3 cells were pretreated with lovastatin for 24 h
before harvest for membrane preparation to decrease any
endogenous p21ras occupancy of potential farnesylation-dependent binding sites. An enriched plasma membrane fraction from lovastatin-treated NIH3T3 cells was prepared by
means of discontinuous Ficoll and sucrose density gradients.
Marker enzyme analysis of the plasma membrane fraction
showed that the specific activity of 59-nucleotidase was 12.5fold enriched in this fraction compared with the initial homogenate. Based on glucose-6-phosphatase activity, the
cross-contamination of the plasma membrane fraction with
microsomes was approximately 11%.
We examined the kinetics of binding of the purified, 125Ip21Ha-ras to the NIH3T3 plasma membranes, subtracting out
nonspecific binding estimated from the binding in the presence
of excess unlabeled ligand. The results (Fig. 3) are consistent
with a saturable binding site for p21Ha-ras, presumably a re-
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FIG. 2. Farnesylation of membrane-associated p21Ha-ras expressed in sf-9 cells. Infected cells were incubated at room temperature overnight with [3H]mevalonolactone (200 mCi/ml) in the presence
of 25 mM lovastatin. Labeled p21Ha-ras derived from the membrane
fraction of infected sf-9 cells was treated with Raney nickel to release
the isoprenoid moiety, which was then analyzed by gas-liquid chromatography and radiodetection (B). The peaks for p21Ha-ras were identified
by comparison of retention time values with the ones generated from
Raney nickel-treated synthetic farnesyl (peak 1) and geranylgeranyl
cysteine methyl esters (peak 2) (A). Recombinant p21Ha-ras released only
the farnesyl group (A, peak 1). FID, flame ionization detector; cps,
counts/s; stds, standards.

ceptor protein. At saturation, approximately 53% of the total
binding was specific binding of 125I-p21Ha-ras to the NIH3T3
plasma membranes. Scatchard analysis of the specific ligand
binding data (Fig. 3, inset) using a one-site model yielded an
estimated Kd and Bmax values of 24.4 6 5.3 nM (mean 6 S.D.)
and 137.3 6 27.1 pmol/mg of protein, respectively. To determine if the binding is reversible under these conditions, 125Ip21Ha-ras was allowed to bind with plasma membranes to saturation, and then a 100-fold excess of unlabeled p21Ha-ras was
added to the assay mixture. After 1 h, nearly half of the counts
had been displaced from the membranes, consistent with reversible association of the ligand with the binding site.
We also examined the effect of the GTP loading on the
membrane binding. To do this, binding was assayed with
p21Ha-ras loaded with GTPgS, a nonhydrolyzable GTP analogue. The GTPgS-loaded p21Ha-ras binding exhibited negative
cooperativity, with an n value of 0.0342 (Fig. 4).
To verify the protein nature of this putative receptor, we
examined the effect of treatment of the plasma membranes
with heat or trypsin on the binding activity. Treatment of
plasma membranes with either heat or trypsin significantly
decreased 125I-p21Ha-ras binding (Fig. 5). These results clearly
demonstrate that the preferential association of p21Ha-ras with
plasma membranes is due to a nonlipid component, i.e. a protein. Comparison of binding activities of the different membrane fractions from the gradient also confirmed that the putative receptor for p21Ha-ras co-purified with the plasma
membrane-enriched fraction (Fig. 5).
Role of the Farnesyl Group in Receptor Binding—The saturation binding assay described above provides a method for
quantitatively determining the effect of the farnesyl group on
binding of p21Ha-ras to its receptor in plasma membranes. We
performed competitive inhibition studies with baculovirus-generated nonfarnesylated cytosolic p21Ha-ras. The cytosolic protein has been shown to be concentrated in the aqueous layer
after Triton X-114 partitioning and, hence, to be nonlipidated.
We confirmed this for our preparations of the cytosolic protein
by demonstrating that this material could be farnesylated by
reticulocyte lysates in vitro (data not shown). We could not

obtain any inhibition of farnesylated p21Ha-ras by the nonfarnesylated protein at concentrations as much as 1,000-fold
higher than the farnesylated ligand (Fig. 6). On the other hand,
unlabeled, fully processed N, H, or K p21ras prepared from sf-9
cells were all efficient competitive inhibitors.
The farnesylation requirement for receptor binding is indicative of recognition of the polyisoprenoid group. To examine
this point further, we synthesized N-acetyl-S-farnesyl methyl
cysteine, an analogue of the carboxyl-terminal amino acid residue of the p21ras proteins. This compound is a weak competitive inhibitor of p21Ha-ras binding to the receptor (Table I).
Competitive inhibition was also observed with another farnesylated protein, lamin B, and with an S-farnesyl cysteine
methyl ester peptide corresponding to the carboxyl-terminal 15
amino acid residues of prelamin A (Table I). These results
indicate that although the receptor recognizes the polyisoprenoid moiety, binding is also mediated by another domain on the
p21ras protein.
It has been reported that transfection of 3T3 cells with
geranylgeranylated p21Ha-ras (CAAX 5 CVLL) results in a
membrane-associated protein that is transforming when oncogenic but inhibits cellular growth p21Ha-ras when wild type
(22). We considered the possibility that this observation
might reflect some difference in the interaction of this reported (22) geranylgeranylated protein and the wild-type
farnesylated protein with the receptor. Competitive inhibition studies with this CVLL mutant of p21Ha-ras, previously
shown to be geranylgeranylated and to produce growth inhibition, were performed. The results (Fig. 6) indicate that the,
presumably, geranylgeranylated p21Ha-ras has an affinity for
the receptor that is comparable to that of the wild-type p21ras
proteins. These results suggest that the p21ras receptor does
not exhibit a strong discrimination between farnesyl and
geranylgeranyl substituents.
Ligand Blot Analysis of p21Ha-ras Binding Sites in the
Plasma Membrane-enriched Fraction—Another technique that
can visualize a membrane-associated receptor is ligand blotting
(16). In this technique, association of a radioiodinated ligand
with its receptor can be demonstrated by SDS-polyacrylamide
gel electrophoresis separation of the membrane proteins, their
transfer to nitrocellulose filters, and incubation of the filters
with ligand. We applied this method to the p21Ha-ras receptor.
The results (Fig. 7) indicate two bands that appear to be specifically labeled by 125I-p21Ha-ras at 45 and 35 kDa (lane 1); this
binding was almost completely eliminated in the presence of a
100-fold excess of noniodinated farnesylated p21Ha-ras (lane 2).
The binding of 125I-p21Ha-ras with 45 and 35 kDa polypeptides
in ligand blots was not affected in the presence of a 100-fold
excess of nonfarnesylated cytosolic p21Ha-ras (Fig. 7, lane 3).
Binding also was seen to be reduced by doing the blots in the
presence of 5 mM N-acetyl farnesyl methyl cysteine (Fig. 7, lane
4). These results for the proteins visualized by ligand blot are
consistent with the quantitative competitive inhibition of binding seen in Table I. The binding proteins (45 and 35 kDa)
almost exclusively partitioned into the detergent phase with
Triton X-114 (data not shown), which is consistent with their
being intrinsic membrane proteins.
DISCUSSION

Plasma membrane localization of p21ras has been shown to
be critical for both normal and oncogenic signaling activities of
these proteins (23). Elegant mutant expression studies on recombinant p21ras have demonstrated the structural requirements for N, H, and K p21ras protein localization to cell plasma
membranes (5, 24). Plasma membrane association of p21Ha-ras
or p21N-ras requires post-translational modification of the protein by two alkyl groups (24). The expression studies indicate
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FIG. 3. Saturation binding of 125Ip21Ha-ras (farnesylated) to NIH3T3
plasma membranes and Scatchard
plot (one-site model) of specific binding showing estimates of Kd and Bmax.
Aliquots of plasma membranes were incubated with varying concentrations of 125Ip21Ha-ras (5–150 nM) with or without a
100-fold excess of unlabeled p21Ha-ras as
described under “Materials and Methods.” Every data point represents an average (6S.D.) of five replicates of three
independent experiments (n 5 15).

FIG. 4. Binding of 125I-p21Ha-ras loaded with the GTP analogue
GTPgS to NIH3T3 plasma membranes. A Hill plot analysis of the
binding data is also shown. Aliquots of plasma membranes were incubated with varying concentrations of 125I-p21Ha-ras (5–150 nM) with or
without a 100-fold excess of unlabeled p21Ha-ras in the presence of 30 mM
GDP or 25 mM GTPgS as described under “Materials and Methods.”
Every data point represents an average (6S.D.) of three replicates of
two independent experiments (n 5 6). Y, fractional saturation.

that post-translational modification by acylation (palmitoylation at Cys-181 or Cys-185 or N-terminal myristoylation)
and/or prenylation (farnesylation or geranylgeranylation) produces at least some association of the dialkylated protein with
plasma membranes. Mutants of p21Ha-ras that only undergo
farnesylation do not exhibit plasma membrane association of
p21ras as detected by immunofluorescence. The carboxyl terminus of p21Ha-ras thus possesses a dialkyl structure that appears
to be required for its plasma membrane binding. It has been
noted (24) that the close proximity of the N terminus and C
terminus of p21ras would cause myristoylated and carboxylterminal-monolipidated p21ras to present a structure comparable to that of the wild-type protein. The recognition site for this
structure in the plasma membrane has been hypothesized to be
a receptor or docking protein that mediates assembly of p21ras
into the membrane where it is stabilized by nonspecific lipidlipid interactions.
The studies reported here, confirm and extend these ideas.
Based on the amount of protein per cell (;1 mg/107 cells) and
the fraction of total cellular protein found in the plasma
membrane-enriched fraction (;5%) used in our binding studies, we estimate that there are approximately 5 3 105 p21ras

FIG. 5. Binding of 125I-p21Ha-ras (farnesylated) to different subcellular fractions of NIH3T3 cells. NIH3T3 plasma membrane and
microsomal and large particulate fractions were assayed for p21Ha-ras
binding activity with 50 nM p21Ha-ras. In one set of experiments, the
fractions were pretreated with trypsin or trypsin inactivated with protease inhibitor mix. In another series of experiments, subcellular fractions were also inactivated by incubation at 100 °C for 5 min. The
binding studies were carried out as described under “Materials and
Methods.” The mean and S.D. of three determinations from two independent experiments are shown.

receptors/cell. This can be compared with the ;5 3 105 sites/
cell reported for transmembrane-bridging mitogenic peptide
receptors such as those for platelet-derived growth factor and
epidermal growth factor (25), which are believed to transduce
growth signals through p21ras. If nothing else, this number
suggests that the total number of such receptors is relatively
small and, therefore, inconsistent with being a lipid or a
ubiquitous membrane protein. The Kd (25 nM) we observe for
p21Ha-ras binding can be compared with that seen for another
farnesylation-dependent protein-protein interaction of
p21ras. In vitro binding of p21Ki-ras(4B) to human SOS1 has
been shown to be absolutely dependent on farnesylation and
exhibits 50% saturation at 200 nM (26). In this comparison,
the farnesylation-dependent binding we have observed appears to be at relatively high affinity.
The ligand blot data we report are also consistent with a
farnesyl group-dependent binding site for p21ras in plasma
membranes. Other p21ras binding activities, with the exception
of the cytosolic hSOS1 protein noted above, do not exhibit such
a requirement for farnesylation. For example, it has been reported (27) that the 21–24-kDa protein caveolin has p21Ha-ras
binding activity. Caveolin was shown not to have an absolute
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FIG. 6. Binding of 125I-p21Ha-ras with NIH3T3 plasma membranes in the presence of unlabeled competitors. Nonfarnesylated p21Ha-ras, bovine serum albumin, p21N-ras, p21Ki-ras, CVLLp21Ha-ras, rat liver lamin B, LLGNSSPRTQSPQNCfarnesyl, and N-acetyl
farnesyl methyl cysteine (5 nM to 5 mM) were added with 125I-p21Ha-ras
(50 nM) under binding conditions outlined under “Materials and Methods.” Calculations of IC50 and Ki values were performed as described
(11). BSA, bovine serum albumin.
TABLE I
Competitive inhibition of p21Ha-ras binding to plasma membranes
Competitor

IC50

Kd or Ki
(mean 6 S.E.)

61.6
106.4
135.5
162.6
183.6
379.4
545.7
No competition
No competition

27.7 6 3.4
47.9 6 7.3
61.1 6 8.2
73.2 6 8.9
82.8 6 13.3
171.0 6 23.2
246.0 6 38.7

nM

Unlabeled farnesylated p21Ha-ras
p21Ki-ras
p21N-ras
CVLL-p21Ha-ras
Lamin B
N-acetyl farnesyl methyl cysteine
LLGNSSPRTQSPQNCfarnesyl
Nonfarnesylated p21Ha-ras
Bovine serum albumin

studies reported here are consistent with an analogous p21ras
receptor that recognizes the lipid moiety but, based on the
weak competition for binding of N-acetyl farnesyl cysteine
methyl ester (which is also detectable in the ligand blots) and
the prelamin A peptide, recognizes other structural features
of p21ras as well.
A plasma membrane receptor for p21ras that recognizes the
protein at least in part through its isoprenoid substituent is, as
noted above, consistent with a large body of literature regarding the effect of site-directed mutations on p21ras localization to
the plasma membrane. There are, however, at least two functional interpretations of such a binding protein. Hancock and
co-workers (24), have suggested that H and N p21ras assemble
into plasma membranes through initial recognition of two alkyl
groups by a docking protein. The bound protein is then unloaded into the membrane bilayer where it is stabilized by
hydrophobic interaction of the alkyl groups with the lipid bilayer. The binding activity we have identified is certainly consistent with this hypothesis. A second possibility is that the
p21ras receptor represents a terminal destination for p21ras. It
should be noted in this regard that the Kd for the p21ras receptor is much lower than that reported (28) for binding of the
alkylated carboxymethylated model p21Ki-ras4B peptide (Kd 5
480 nM) to lipid vesicles, and therefore p21ras receptors could be
occupied even though surrounded by lipid bilayer. It is also
possible that both the p21ras receptor and the lipid bilayer are
terminal destinations for p21ras but mediate different
functions.
The reversibility of binding of the farnesylated p21Ha-ras as
well as the negatively cooperative binding kinetics observed
with GDP and GTPgS-loaded p21Ha-ras is consistent with the
possibility that the association of p21Ha-ras with the plasma
membrane may be regulated. The sigmoidal kinetics observed
when the p21Ha-ras is GTP-loaded suggests that the receptor
may exist as a homodimer in the membrane. In this regard, it
is of interest to note that a pool of farnesylated cytosolic p21ras
has been reported to exist in 3T3-L1 cells (29).
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